Marshall Wace, LLP Galectin Therapeutics Inc Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 52,259 shares of GALT stock, worth $139,008. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,259
Previous 18,825
177.6%
Holding current value
$139,008
Previous $42,000
240.48%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding GALT
# of Institutions
90Shares Held
9.44MCall Options Held
1.16MPut Options Held
1.98M-
Vanguard Group Inc Valley Forge, PA2.13MShares$5.68 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$4.16 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$3.14 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA863KShares$2.29 Million0.0% of portfolio
-
Commonwealth Equity Services, LLC483KShares$1.29 Million0.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $158M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...